The majority of people with T2D are overweight or have obesity. It is important to evaluate the influence of Baseline (BL) BMI on iGlarLixi effectiveness. In the European REALI pooled database, we analyzed patient-level data of 1406 people with uncontrolled T2D initiating iGlarLixi treatment over 24 weeks: 894 (64%) had BL BMI ≥30 kg/m2 and 510 (36%) had BL BMI <30 kg/m2. The overall mean±SD age was 61±9 years. Median T2D duration was 9 years (IQR, 5.0 to 13.0). At BL, mean HbA1c was 9.10% in the BMI ≥30 kg/m2 group and 9.03% in the BMI <30 kg/m2 group. The least-square mean HbA1c change from BL to Week 24 was similar at -1.38% and -1.47%, respectively (Fig 1A). Mean±SD body weight decreased by 2.6±4.9 kg in the BMI ≥30 kg/m2 group and by 0.7±4.4 kg in the BMI <30 kg/m2 group (Fig 1B). The mean iGlarLixi daily dose increased from 0.21 U/kg (20.5 U) at BL to 0.38 U/kg (35.6 U) at Week 24 in the BMI ≥30 kg/m2 group and from 0.23 U/kg (17.7 U) to 0.40 U/kg (30.4 U) in the BMI <30 kg/m2 group. Symptomatic hypoglycemia reports and gastrointestinal side effects were low in both groups. This analysis demonstrated that initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, regardless of Baseline BMI. HbA1c markedly improved in both groups, with a more prominent weight loss in people with obesity.
J.T. Kis: None. J. Seufert: Consultant; Sanofi. Advisory Panel; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim, Sanofi, Lilly Diabetes. Advisory Panel; Abbott. Speaker's Bureau; Abbott, Novo Nordisk. Advisory Panel; Novo Nordisk. M. Haluzik: Advisory Panel; Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Johnson & Johnson Medical Devices Companies. Consultant; Merck & Co., Inc., Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Johnson & Johnson Medical Devices Companies, Novatin. Research Support; Sanofi. Speaker's Bureau; Sanofi, Novo Nordisk. C. Vera: None. M. Tournay: None. M. Bonnemaire: None. N. Freemantle: Consultant; Sanofi, ALK-Abelló, AstraZeneca, Vertex Pharmaceuticals Incorporated. Other Relationship; ICON. Consultant; Thea. C. Guja: Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Berlin-Chemie AG, Eli Lilly and Company, Novo Nordisk, Pfizer Inc., Sanofi, Servier Laboratories, KRKA, Viatris Inc.
Sanofi
